Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
July 4, 2024Surgical Oncology InsightOpen Access

Hyperthermic Intraperitoneal Chemotherapy (HIPEC) vs. Postoperative Intraperitoneal (IP) Chemotherapy - Impact on Health-Related Quality of Life in Primary Ovarian Cancer Patients after Cytoreductive Surgery

View Full Paper
Ask AI
Bookmark
Share

Authors

LFLuis Felipe Falla-ZúñigaASArmando SardiMKMary Caitlin King

Discussion

Loading...

Member takes

Overview

Key Points

Key points are not available for this paper at this time.

Cite This Study

Falla-Zúñiga et al. (2024) studied this question.

synapsesocial.com/papers/68e615dfb6db6435875a8ae0https://doi.org/10.1016/j.soi.2024.100073
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 11325 Impact of HIPEC introduction in cytoreduction for ovarian cancer of ovarian origin: a real-world population study2024
  2. 2QUALITY OF LIFE OF PATIENTS AFTER CYTOREDUCTIVE SURGERY AND HYPERTHERMIC INTRAPERITONEAL CHEMOTHERAPY: A SYSTEMATIC REVIEW2026
  3. 3742 Neoadjuvant chemotherapy plus interval cytoreductive surgery with or without hyperthermic intraperitoneal chemotherapy (NIHIPEC) in the treatment of advanced ovarian cancer: a multicentric propensity score study2024
  4. 41085 Survival and adverse treatment effects of hyperthermic intraperitoneal chemotherapy (HIPEC) in the treatment of advanced stage ovarian cancer2024
  5. 5HIPEC application potential in the treatment of extensive carcinomatosis in ovarian cancer (retrospective study)2024